α7 nicotinic receptor agonists: Potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease

Open Medicinal Chemistry Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 37-56

  Toyohara, Jun ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cognition; Schizophrenia; 7 Nicotinic receptors

Indexed keywords

1 AZABICYCLO[3.2.1]OCTANE 3 AMINE; 1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 2 (3 PYRIDYL) 1 AZABICYCLO[3.2.2]NONANE; 2 (5 METHYLHEXAHYDROPYRROLO[3,4 C]PYRROL 2 YL)XANTHEN 9 ONE; 2 (5 METHYLOXAZOLO[4,5 B]PYRIDIN 2 YL) 2,5 DIAZABICYCLO[3.2.2]NONANE; 2 METHYL 5 (6 PHENYLPYRIDAZIN 3 YL)OCTAHYDROPYRROLO[3,4 C]PYRROLE; 2,3 DIHYDRO N [QUINUCLIDIN 3 YL]BENZO[B][1,4]DIOXINE 6 CARBOXAMIDE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (4 DIMETHYLAMINOBENZYLIDINE)ANABASEINE; 3 (4 DIMETHYLAMINOCINNAMYLIDINE); 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; 3 [2 (BENZO[B]THIOPHEN 2 YL) 2 OXOETHYL] 1 AZABICYCLO[2.2.2]OCTANE; 3' (5 CHLOROTHIOPHEN 2 YL)SPIRO 1 AZABICYCLO[2.2.2]OCTANE 3,5' [1',3']OXAZOLIDIN 2' ONE; 3' [3 METHYLBENZO[B]THIOPHEN 5 YL]SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,5' OXAZOLIDIN] 2' ONE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; A 582941; A 844606; AMYLOID BETA PROTEIN; ANABASINE; AR R17779; BUNGAROTOXIN RECEPTOR; CLOZAPINE; CP 810123; N (1 AZABICYCLO[3.2.1]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N (3 QUINUCLIDINYL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N [1 AZABICYCLO[2.2.2]OCT 3 YL] 7 [2 (METHOXY)PHENYL] 1 BENZOFURAN 2 CARBOXAMIDE; N [2 [(PYRIDIN 3YL)METHYL]QUINUCLIDIN 3 YL]BENZOFURAN 2 CARBOXAMIDE; NICOTINIC AGENT; ONDANSETRON; PHA 568487; PLACEBO; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,5' OXAZOLIDIN 2' ONE]; TC 1698; TC 5619; TILORONE; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; W 56203;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC POLYMORPHISM; HEART VENTRICLE TACHYCARDIA; HUMAN; MEMORY DISORDER; NAUSEA; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RESTLESSNESS; SCHIZOPHRENIA; SENSORY GATING; SINGLE DRUG DOSE;

EID: 77954584878     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501004010037     Document Type: Article

References (159)

1. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol., 2000, 61, 75-111
2. Dani, J.A.; Ji, D.; Zhou, F.M. Selective dopamine filter of glutamate striatal afferents. Neuron, 2001, 31, 349-352
3. Hogg, R.C.; Raggenbass, M.; Bertrand, D. Nicotinic acetylcholine receptors: from structure to brain function. Rev. Physiol. Biochem. Pharmacol., 2003, 147, 1-46
4. Dajas-Bailador, F.; Wonnacott, S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci., 2004, 25, 317-324
5. Buisson, B.; Bertrand, D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol. Sci., 2002, 23, 130-136
6. Nomikos, G.G.; Schilström, B.; Hildebrand, B.E.; Panagis, G.; Grenhoff, J.; Svensson, T.H. Role of 7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res., 2000, 113, 97-103
7. Mathieu-Kia, A.M.; Kellogg, S.H.; Butelman, E.R.; Kreek, M.J. Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl.), 2002, 162, 102-118
8. Picciotto, M.R.; Caldarone, B.J.; King, S.L.; Zachariou, V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology, 2000, 22, 451-465
9. Picciotto, M.R.; Corrigall, W.A. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J. Neurosci., 2002, 22, 3338-3341
10. Martin, L.F.; Kem, W.R.; Freedman, R. 7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl.), 2004, 174, 54-64
11. Newhouse, P.A.; Potter, A.; Singh, A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol., 2004, 4, 36-46
12. Benowitx, N.L. Pharmacology of nicotine: addiction and therapeutics. Ann. Rev. Pharmacol. Toxicol., 1996, 36, 597-613
13. Holladay, M.W.; Dart, M.J.; Lynch, J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem., 1997, 40, 4169-4194
14. Léna, C.; Changeux, J.P. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr. Opin. Neurobiol., 1997, 7, 674-682
15. Buccafusco, J.J.; Terry, A.V. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J. Pharmacol. Exp. Ther., 2000, 295, 438-446
16. Gotti, C.; Fornasari, D.; Clementi, F. Human neuronal nicotinic receptors. Prog. Neurobiol., 1997, 53, 199-237
17. Gotti, C.; Carbonnelle, E.; Moretti, M.; Zwart, R.; Clementi, F. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav. Brain Res., 2000, 113, 183-192
18. Lloyd, G.K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther., 2000, 292, 461-467
19. Dwoskin, L.P.; Crooks, P.A. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J. Pharmacol. Exp. Ther., 2001, 298, 395-402
20. Schmitt, J.D. Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem., 2000, 7, 749-800
21. Levin, E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol., 2002, 53, 633-640
22. Hogg, R.C.; Bertrand, D. Nicotinic acetylcholine receptors as drug targets. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 123-130
23. Hashimoto, K.; Koike, K.; Shimizu, E.; Iyo, M. 7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr. Med. Chem. CNS Agents, 2005, 5, 171-184
24. Flores, C.M.; Rogers, S.W.; Pabreza, L.A.; Wolfe, B.B.; Kellar, K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of 4 and 2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol., 1992, 41, 31-37
25. Marks, M.J.; Collins, A.C. Characterization of nicotine binding in mouse brain and comparison with the binding of -bungarotoxin and quinuclidinyl benzilate. Mol. Pharmacol., 1982, 22, 554-564
26. Broide, R.S.; Leslie, F.M. The 7 nicotinic acetylcholine receptor in neuronal plasticity. Mol. Neurobiol., 1999, 20, 1-16
27. Jones, S.; Sudweeks, S.; Yakel, J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci., 1999, 22, 555-561
28. Cordero-Erausquin, M.; Marubio, L.M.; Klink, R.; Changeux, J.P. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharamacol. Sci., 2000, 21, 211-217
29. Picciotto, M.R.; Caldarone, B.J.; Brunzall, D.H.; Zachariou, V.; Stevens, T.R.; King, S.L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol. Ther., 2001, 92, 89-108
30. Champtiaux, N.; Changeux, J.P. Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog. Brain Res., 2004, 145, 235-251
31. Papke, R.L.; Bencherif, M.; Lippiello, P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the 7 subtype. Neurosci. Lett., 1996, 213, 201-204
32. Alkondon, M.; Pereira, E.F.R.; Cortes, W.S.; Maelicke, A.; Albuquerque, E.X. Choline is a selective agonist of 7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci., 1997, 9, 2734-2742
33. Alkondon, M.; Pereira, E.F.R.; Braga, M.F.M.; Albuquerque, E.X. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of 7 receptors. J. Physiol.(Paris), 1998, 92, 309-316
34. Uteshev, V.V.; Meyer, E.M.; Papke, R.L. Regulation of neuronal function by choline and 4OH-GTS-21 through 7 nicotinic receptors. J. Neurophysiol., 2003, 89, 1797-1806
35. Berg, D.K.; Conroy, W.G. Nicotinic 7 receptors: synaptic options and downstream signaling in neurons. J. Neurobiol., 2002, 53, 512-523
36. Gray, R.; Rajan, A.S.; Radcliffe, K.A.; Yakehiro, M.; Dani, J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature, 1996, 383, 713-716
37. Hashimoto, K.; Shimizu, E.; Iyo, M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev., 2005, 1, 151-163
38. Hashimoto, K.; Hattori, E. Part II. Candidate Gene and Models. 4. Neurotransmission. In: Neurogenetics of Psychiatric Disorders. Sawa, A., McInnis, M.G., Eds.; Informa Healthcare: New York, 2007, pp. 81-100
39. Hashimoto, K.; Iyo, M. Amyloid cascade hypothesis of Alzheimer's disease and 7 nicotinic receptor. Nihon Shinkei Seishin Yakurigaku Zasshi 2002, 22, 3-13
40. Bourin, M.; Ripoll, N.; Dailly, E. Nicotinic receptors and Alzheimer's disease. Curr. Med. Res. Opin., 2003, 19, 169-177
41. D'Andrea, M.R.; Nagele, R.G. Targeting the 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Des., 2006, 12, 677-684
42. 125I]bungarotoxin and [3H]nicotine. Acta Physiol. Scand., 1988, 132, 1-14
43. Freedman, R.; Wetmore, C.; Strömberg, I.; Leonard, S.; Olson, L. -Bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J. Neurosci., 1993, 13, 1965-1975
44. Freedman, R.; Adler, L.E.; Bickford, P.; Byerley, W.; Coon, H.; Cullum, C.M.; Griffith, J.; Harris, J.G.; Leonard, S.; Miller, C.; Myles-Worsey, M.; Nagamoto, H.T.; Rose, G.; Waldo, M. Schizophrenia and nicotinic receptors. Harv. Rev. Psychiatry, 1994, 2, 179-192
45. Freedman, R.; Hall, M.; Adler, L.E.; Leonard, S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry, 1995, 38, 22-33
46. Court, J.; Spurden, D.; Lloyd, S.; McKeith, I.; Ballard, C.; Cairns, N.; Kerwin, R.; Perry, R.; Perry, E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: -bungarotoxin and nicotine binding in the thalamus. J. Neurochem., 1999, 73, 1590-1597
47. Guan, Z.Z.; Zhang, X.; Blennow, K.; Nordberg, A. Decreased protein level of nicotinic receptor 7 subunit in the frontal cortex from schizophrenic brain. Neuroreport, 1999, 10, 1779-1782
48. Marutle, A.; Zhang, X.; Court, J.; Piggott, M.; Johnson, M.; Perry, R.; Perry, E.; Nordberg, A. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J. Chem. Neuroanat., 2001, 22, 115-126
49. Leonard, S.; Adams, C.; Breese, C.R.; Adler, L.E.; Bickford, P.; Byerley, W.; Coon, H.; Griffith, J.M.; Miller, C.; Myles-Worsley, M.; Nagamoto, H.T.; Rollins, Y.; Stevens, K.E.; Waldo, M.; Freedman, R. Nicotinic receptor function in schizophrenia. Schizophr. Bull., 1996, 22, 431-445
50. Freedman, R.; Adams, C.E.; Leonard, S. The 7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J. Chem. Neuroanat., 2000, 20, 299-306
51. Perl, O.; Ilani, T.; Strous, R.D.; Lapidus, R.; Fuchs, S. The 7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J., 2003, 17, 1948-1950
52. Braff, D.L.; Geyer, M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry, 1990, 47, 181-188
53. Adler, L.E.; Olincy, A.; Waldo, M.; Harris, J.G.; Giffith, J.; Stevens, K.; Flach, K.; Nagamoto, H.; Bickford, P.; Leonard, S.; Freedman, R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull., 1998, 24, 189-202
54. Braff, D.; Freedman, R. Neuropsychopharmacology, In: The Fifth Generation of Progress; Davis. K.L., Charney, D., Coyle, J.T., Nemeroff, C.N., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2003; pp. 703-716
55. Freedman, R.; Adler, L.E.; Gerhardt, G.A.; Waldo, M.; Baker, N.; Rose, G.M.; Drebing, C.; Nagamoto, H.; Bickford-Wimer, P.; Franks, R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull., 1987, 13, 669-678
56. Adler, L.E.; Hoffer, L.J.; Griffith, J.; Waldo, M.C.; Freedman, R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry, 1992, 32, 607-616
57. Adler, L.E.; Hoffer, L.J.; Wiser, A.; Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry, 1993, 150, 1856-1861
58. Freedman, R.; Coon, H.; Myles-Worsley, M.; Orr-Urtreger, A.; Olincy, A.; Davis, A.; Polymeropoulos, M.; Holik, J.; Hopkins, J.; Hoff, M.; Rosenthal, J.; Waldo, M.C.; Reimherr, F.; Wender, P.; Yaw, J.; Young, D.A.; Breese, C.R.; Adams, C.; Patterson, D.; Adler, L.E.; Kruglyak, L.; Leonard, S.; Byerley, W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA, 1997, 94, 587-592
59. Kaufmann, C.A.; Suarez, B.; Malaspina, D.; Pepple, J.; Svrakic, D.; Markel, P.D.; Meyer, J.; Zambuto, C.T.; Schmitt, K.; Matise, T.C.; Harkavy Friedman, J.M.; Hampe, C.; Lee, H.; Shore, D.; Wynne, D.; Faraone, S.V.; Tsuang, M.T.; Cloninger, C.R. NIMH genetics initiative millenium schizophrenia consortium: linkage analysis of African-American pedigrees. Am. J. Med. Genet., 1998, 81, 282-289
60. Leonard, S.; Gault, J.; Moore, T.; Hopkins, J.; Robinson, M.; Olincy, A.; Adler, L.E.; Cloninger, C.R.; Kaufmann, C.A.; Tsuang, M.T.; Faraone, S.V.; Malaspina, D.; Svrakic, D.M.; Freedman, R. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH genetics initiative. Am. J. Med. Genet., 1998, 81, 308-312
61. Gault, J.; Robinson, M.; Berger, R.; Drebing, C.; Logel, J.; Hopkins, J.; Moore, T.; Jacobs, S.; Meriwether, J.; Choi, M.J.; Kim, E.J.; Walton, K.; Buiting, K.; Davis, A.; Breese, C.; Freedman, R.; Leonard, S. Genomic organization and partial duplication of the human 7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics, 1998, 52, 173-185
62. Leonard, S.; Gault, J.; Hopkins, J.; Logel, J.; Vianzon, R.; Short, M.; Drebing, C.; Berger, R.; Venn, D.; Sirota, P.; Zerbe, G.; Olincy, A.; Ross, R.G.; Adler, L.E.; Freedman, R. Association of promoter variants in the 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry, 2002, 59, 1085-1096
63. De Luca, V.; Wong, A.H.C.; Muller, D.J.; Wong, G.W.H.; Tyndale, R.F.; Kennedy, J.L. Evidence of association between smoking and 7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology, 2004, 29, 1522-1526
64. Simosky, J.K.; Stevens, K.E.; Freedman, R. Nicotinic agonists and psychosis. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 433-442
65. Leonard, S. Consequences of low levels of nicotinic acetylcholine receptors in schizophrenia for drug development. Drug Dev. Res., 2003, 60, 127-136
66. Freedman, R.; Leonard, S.; Waldo, M.; Gault, J.; Olincy, A.; Adler, L.E. Characterization of allelic variants at chromosome 15q14 in schizophrenia. Genes Brain Behav., 2006, 5 (Suppl 1), 14-22
67. Zammit, S.; Spurlock, G.; Williams, H.; Norton, N.; Williams, N.; O'Donovan, M.C.; Owen, M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry, 2007, 191, 402-407
68. Dempster, E.L.; Toulopoulou, T.; McDonald, C.; Bramon, E.; Walshe, M.; Wickham, H.; Sham, P.C.; Murray, R.M.; Collier, D.A. Episodic memory performance predicted by the 2bp deletion in exon 6 of the alpha 7-like nicotinic receptor subunit gene. Am. J. Psychiatry, 2006, 163, 1832-1034
69. Olincy, A.; Stevens, K.E. Treating schizophrenia symptoms with an 7 nicotinic agonist, from mice to men. Biochem. Pharmacol., 2007, 74, 1192-1201
70. Adams, C.E.; Stevens, K.E. Evidence for a role of nicotinic acetylcholine receptor in schizophrenia. Front. Biosci., 2007, 12, 4755-4772
71. Bowen, D.M. Biomedical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In: Biological Aspects of Alzheimer's Disease; Katzman, R., Ed.; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1983; pp. 219-232
72. Cummings, J.L.; Benson, D.F. The role of the nucleus basalis of Meynert and dementia: Review and reconsideration. Alzheimer Dis. Assoc. Disord., 1987, 1, 128-145
73. Perry, E.K.; Court, J.A.; Piggott, M.A.; Perry, R.H. Cholinergic component of dementia and aging. In: Dementia and Normal Aging; Huppert, F.A.; Brayne, C.; O'Connor, D.W. Eds.; Cambridge University Press: New York, 1994; pp. 437-469
74. Davies, P.; Feisullin, S. Postmortem stability of -bungarotoxin binding sites in mouse and human brain. Brain Res., 1981, 216, 449-454
75. Sugaya, K.; Giacobini, E.; Chiappinelli, V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res., 1990, 27, 349-359
76. Hellström-Lindhal, E.; Mousavi, M.; Zhang, X.; Ravid, R.; Nordberg, A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: Comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res., 1999, 66, 94-103
77. Guan, Z.-Z.; Zhang, X.; Ravid, R.; Nordberg, A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem., 2000, 74, 237-243
78. Martin-Ruiz, C.M.; Court, J.A.; Molnar, E.; Lee, M.; Gott, C.; Mamalki, A.; Tsouloufis, T.; Tzartos, S.; Ballard, C.; Perry, R.H.; Perry, E.K. 4 but not 3 and 7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem., 1999, 73, 1635-1640
79. Burghaus, L.; Schütz, U.; Krempel, U.; de Vos, R.A.; Jansen Steur, E.N.; Wevers, A.; Lindstrom, J.; Schröder, H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimar's patients. Brain Res. Mol. Brain Rev., 2000, 76, 385-388
80. Wevers, A.; Monteggia, L.; Nowacki, S.; Bloch, W.; Schütz, U.; Lindstrom, J.; Pereira, E.F.; Eisenberg, H.; Giacobini, E.; de Vos, R.A.; Steur, E.N.; Maelicke, A.; Albuquerque. E.X.; Schröder, H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease-histotopographical correlation with amyloid plaques and hyperphosphorylated tauprotein. Eur. J. Neurosci., 1999, 11, 2551-2565
81. Court, J.; Martin-Ruiz, C.; Piggott, M.; Spurden, D.; Griffiths, M.; Perry, E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol. Psychiatry, 2001, 49, 175-184
82. Counts, S.E.; He, B.; Che, S.; Iknomovic, M.D.; DeKosky, S.T.; Ginsberg, S.D.; Mufson, E.J. 7 Nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch. Neurol., 2007, 64, 1771-1776
83. Ikonomovic, M.D.; Wecker, L.; Abrahamson, E.E.; Wuu, J.; Counts, S.E.; Ginsberg, S.D.; Mufson, E.J.; Dekosky, S.T. Cortical 7 nicotinic acetylcholine receptor and -amyloid levels in early Alzheimer's disease. Arch. Neurol., 2009, 66, 646-651
84. Carson, R.; Craig, D.; Hart, D.; Todd, S.; McGuinness, B.; Johnston, J.A.; O'Neill, F.A.; Ritchie, C.W.; Passmore, A.P. Genetic variation in the 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromol. Med., 2008, 10, 377-384
85. Jessen, F.; Kucharski, C.; Fries, T.; Papassotiropoulos, A.; Hoenig, K.; Maier, W.; Heun, R. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am. J. Psychiatry, 2001, 158, 1319-1321
86. Wang, H.Y.; Lee, D.H.; D'Andrea, M.R.; Peterson, P.A.; Shank, R.P.; Reitz, A.B. Amyloid1-42 binds to 7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J. Biol. Chem., 2000, 275, 5626-5632
87. Wang, H.Y.; Lee, D.H.; Davis, C.B.; Shank, R.P. Amyloid petide A 1-42 binds selectively and with pico-molar affinity to 7 nicotinic acetylcholine receptors. J. Neurochem., 2000, 75, 1155-1161
88. Nagele, R.G.; D'Andrea, M.R.; Anderson, W.J.; Wang, H.-Y. Intracellular accumulation of -amyloid1-42 in neurons is facilitated by the 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience, 2002, 110, 199-211
89. Wang, H.Y.; Li, W.; Benedetti, N.J.; Lee, D.H. 7 Nicotinic acetylcholine receptors mediate -amyloid peptides induced tau protein pshophorylation. J. Biol. Chem., 2003, 278, 31547-31553
90. Liu, Q.S.; Kawai, H.; Berg, D.K. Amyloid peptide blocks the response of 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci., USA, 2001, 48, 4734-4739
91. Pettit, D.L.; Shao, Z.; Yakel, J.L. -Amyloid1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci., 2001, 21(RC120), 1-5
92. Lee, D.H.; Wang, H.Y. Differential physiologic responses of 7 nicotinic acetylcholine receptors to -amyloid1-40 and -amyloid1-42. J. Neurobiol., 2003, 55, 25-30
93. Dziewczapolski, G.; Glogowski, C.M.; Masliah, E.; Heinemann, S.F. Deletion of the 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci., 2009, 29, 8805-8815
94. Wang, H.Y.; Stucky, A.; Liu, J.; Shen, C.; Trocme-Thibierge, C.; Morain, P. Dissociating -amyloid from 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J. Neurosci., 2009, 29, 10961-10973
95. Kem, W.R. Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Invert. Neurosci., 1997, 3, 251-259
96. 125I--bungarotoxin receptor subtypes. Mol. Pharmacol., 1995, 47, 164-171
97. Briggs, C.A.; Anderson, D.J.; Brioni, J.D.; Buccafusco, J.J.; Buckley, M.J.; Campbell, J.E.; Decker, M.W.; Donnelly-Roberts, D.; Elliott, R.L.; Gopalakrishnan, M.; Holladay, M.W.; Hui, Y.H.; Jackson, W.J.; Kim, D.J.; Marsh, K.C.; O'Neill, A.; Prendergast, M.A.; Ryther, K.B.; Sullivan, J.P.; Arneric, S.P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav., 1997, 57, 231-241
98. Meyer, E.M.; Kuryatov, A.; Gerzanich, V.; Lindstrom, J.; Papke, R.L. Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat 7 nicotinic receptors. J. Pharmacol. Exp. Ther., 1998, 287, 918-925
99. Kem, W.R.; Mahnir, V.; Prokai, L.; Papke, R.L.; Cao, X.; LeFrancois, S.; Wildeboer, K.; Prokai-Tatrai, K.; Porter-Papke, J.; Soti, F. Hydroxy metabolites of the Alzheimer's drug candidate 3- [(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS- 21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol. Pharmacol., 2004, 65, 56-67
100. Kem, W.R. The brain 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res., 2000, 113, 169-181
101. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K.A.; Kramer, W.G.; Clody, D.E.; Burnett, A.L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology, 2003, 28, 542-551
102. Olincy, A.; Harris, J.G.; Johnson, L.L.; Pender, V.; Kongs, S.; Allensworth, D.; Ellis, J.; Zerbe, G.O.; Leonard, S.; Stevens, K.E.; Stevens, J.O.; Martin, L.; Adler, L.E.; Soti, F.; Kem, W.R.; Freedman, R. Proof-of-concept trial of an 7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry, 2006, 63, 630-638
103. Freedman, R.; Olincy, A.; Buchanan, R.W.; Harris, J.G.; Gold, J.M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M.P.; Kutnick, J.; Pender, V.; Martin, L.F.; Stevens, K.E.; Wagner, B.D.; Zerbe, G.O.; Soti, F.; Kem, W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry, 2008, 165, 1040-1047
104. Hashimoto, K. Nausea associated with a nicotinic agonist therapy in schizophrenia. Clin. Psychopharmacol. Neurosci., 2009; 7, 26-27
105. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J. II., Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5 -oxazolidin-2 - one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the 7 nicotinic acetylcholine receptor. J. Med. Chem., 2000, 43, 4045-4050
106. Grottick, A.J.; Trube, G.; Corrigall, W.A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G.A. Evidence that nicotinic 7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther., 2000, 294, 1112-1119
107. Grottick, A.J.; Wyler, R.; Higgins, G.A. The 4 2 agonist SIB 1765F, but not the 7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology, (Berl.), 2000, 150, 233-236
108. Levin, E.D.; Bettegowda, C.; Blosser, J.; Gordon, J. AR-R17779, and 7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol., 1999, 10, 675-680
109. Sydserff, S.; Sutton, E.J.; Song, D.; Quirk, M.C.; Maciag, C.; Li, C.; Jonak, G.; Gurley, D.; Gordon, J.C.; Christian, E.P.; Doherty, J.J.; Hudzik, T.; Johnson, E.; Mrzljak, L.; Piser, T.; Smagin, G.N.; Wang, Y.; Widzowski, D.; Smith, J.S. Selective 7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem. Pharmacol., 2009, 78, 880-888
110. Macor, J.E.; Wu, E. Azabicyclic esters of carbamic acids useful in therapy. International Application No.: PCT/SE1997/000294, WO 97/30998, Aug. 28, 1997
111. Tatsumi, R.; Seio, K.; Fujio, M.; Katayama, J.; Horikawa, T.; Hashimoto, K.; Tanaka, H. (+)-3-[2-(Benzo[b]thiophen-2-yl)-2- oxoethyl]-1- azabicyclo[2.2.2]octane as potent agonists for the 7 nicotinic acetylcholine receptor. Bioorg. Med. Chem., 2004, 14, 3781-3784
112. Tatsumi, R.; Fujio, M.; Satoh, H.; Katayama, J.; Takanashi, S.; Hashimoto, K.; Tanaka, H. Discovery of the 7 nicotinic acetylcholine receptor agonists. (R)-3 -(5-Chlorothiophen-2- yl)spiro-1-azabicyclo[2.2.2]octane-3,5 -[1,3]oxazolidin-2 -one as a novel, potent, selective, and orally bioavailable ligand. J. Med. Chem., 2005, 48, 2678-2686
113. Tatsumi, R.; Fujio, M.; Takanashi, S.; Numata, A.; Katayama, J.; Satoh, H.; Shiigi, Y.; Maeda, J.; Kuriyama, M.; Horikawa, T.; Murozono, T.; Hashimoto, K.; Tanaka, H. (R)-3 -(3- methylbenzo[b]thiophen-5-yl)spiro[1- azabicyclo[2,2,2]octane- 3,5 -oxazolidin]-2 -one, a novel and potent 7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J. Med. Chem., 2006, 49, 4374-4383
114. Marrero, M.B.; Papke, R.L.; Bhatti, B.S.; Shaw, S.; Bencherif, M. The neuroprotective effect of 2-(3-pyridyl)-1- azabicyclo[3.2.2]nonane (TC-1698), a novel 7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J. Pharmacol. Exp. Ther., 2003, 309, 16-27
115. Marzurov, A.; Klucil, J.; Miao, L.; Philips, T.Y.; Seamans, A.; Schmitt, J.D.; Hauser T.A.; Johnson Jr., R.T.; Miller, C. 2- (Arylmethyl)-3-substituted quinuclidines as selective 7 nicotinic receptor ligands. Bioorg. Med. Chem. Lett., 2005, 15, 2073-2077
116. Hauser, T.A.; Kucinski, A.; Jordan, K.G.; Gatto, G.J.; Wetsinger, S.R.; Hesse, R.A.; Stachowiak, E.K.; Stachowiak, M.K.; Papke, R.L.; Lippiello, P.M.; Bencherif, M. TC-5619: an 7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol., 2009, 78, 803-812
117. Bodnar, A.L.; Cortes-Burgos, L.A.; Cook, K.K.; Dinh, D.M.; Groppi, V.E.; Hajos, M.; Higdon, N.R.; Hoffmann, W.E.; Hurst, R.S.; Myers, J.K.; Rogers, B.N.; Wall, T.M.; Wolfe, M.L.; Wong, E. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of 7 nicotinic acetylcholine receptors. J. Med. Chem., 2005, 48, 905-908
118. Hajós, M.; Hurst, R.S.; Hoffmann, W.E.; Krause, M.; Wall, T.M.; Higdon, N.R.; Groppi, V.E. The selective 7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1- Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther., 2005, 312, 1213-1222
119. Wishka, D.G.; Walker, D.P.; Yates, K.M.; Reitz, S.C.; Jia, S.; Myers, J.K.; Olson, K.L.; Jacobsen, E.J.; Wolfe, M.L.; Groppi, V.E.; Hanchar, A.J.; Thornburgh, B.A.; Cortes-Burgons, L.A.; Wong, E.H.F.; Staton, B.A.; Raub, T.J.; Higdon, N.R.; Wall, T.M.; Hurst, R.S.; Walters, R.R.; Hoffmann, W.E.; Hajos, M.; Franklin, S.; Carey, G.; Gold, L.H.; Cook, K.K.; Sands, S.B.; Zhao, S.X.; Soglia, J.R.; Kalgutkar, A.S.; Arneric, A.P.; Rogers, B.N. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3- c]pyridine-5-carboxamide, an agonist of the 7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure activity relationship. J. Med. Chem., 2006, 49, 4425-4436
120. Walker, D.P.; Wishka, D.G.; Piotrowski, D.W.; Jia, S.; Reitz, S.C.; Yates, K.M.; Myers, J.K.; Vetman, T.N.; Margolis, B.J.; Jacobsen, E.J.; Acker, B.A.; Groppi, V.E.; Wolfe, M.L.; Thornburgh, B.A.; Tinholt, P.M.; Cortes-Burgos, L.A.; Walters, R.R.; Hester, M.R.; Seest, E.P.; Dolak, L.A.; Han, F.; Olson, B.A.; Fitzgerald, L.; Staton, B.A.; Raub, T.J.; Hajos, M.; Hoffmann, W.E.; Li, K.S.; Higdon, N.R.; Wall, T.M.; Hurst, R.S.; Wong, E.H.F.; Rogers, B.N. Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as 7 nicotinic acetylcholine receptor agonists. Bioorg. Med. Chem., 2006, 14, 8219-8248
121. Acker, B.A.; Jacobsen, E.J.; Rogers, B.N.; Wishka, D.G.; Reitz, S.C.; Piotrowski, D.W.; Myers, J.K.; Wolfe, M.L.; Groppi, V.E.; Thornburgh, B.A.; Tinholt, P.M.; Walters, R.R.; Olson, B.A.; Fitzgerald, L.; Staton, B.A.; Raub, T.J.; Krause, M.; Li, K.S.; Hoffmann, W.E.; Hajos, M.; Hurst, R.S.; Walker, D.P. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo-[2,3-c]pyridine-5- carboxamide as an agonist of the 7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett., 2008, 18, 3611-3615
122. Biton, B.; Bergis, O.E.; Galli, F.; Nedelec, A.; Lochead, A.W.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F.; Léonardon, J.; Granger, P.; Debono, M.W.; Bohme, G.A.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vigé, X.; Voltz, C.; Rouquier, L.; Souihac, J.; Santucci, V.; Gueudet, C.; Françon, D.; Steinberg, R.; Griebel, G.; Oury-Donat, F.; George, P.; Avenet, P.; Scatton, B. SSR180711, a novel selective 7 nicotinic receptor partial agonist: (I) binding and functional profile. Neuropsychopharmacology, 2007, 32, 1-16
123. Pichat, P.; Bergis, O.E.; Terranova, J.-P.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. SSR180711, a novel selective 7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 2007, 32, 17-34
124. Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective 7 nicotinic receptor agonist SSR180711. Biol. Psychiatry, 2008, 63, 92-97
125. Thomsen, M.S.; Christensen, D.Z.; Hansen, H.H.; Redrobe, J.P.; Mikkelsen, J.D. 7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology, 2009, 56, 1001-1009
126. Barak, S.; Arad, M.; De Levie, A.; Black, M.D.; Griebel, G.; Weiner, I. Pro-cognitive and antipsychotic efficacy of the 7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 2009, 34, 1753-1763
127. Moser, P.C.; Hitchcock, J.M.; Lister, S.; Moran, P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Brain Res. Rev., 2000, 33, 275-307
128. Weiner, I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl.), 2003, 169, 257-297
129. Hansen, H.H.; Timmermann, D.B.; Peters, D.; Walters, C.; Damaj, M.I.; Mikkelsen, J.D. 7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J. Neurosci. Res., 2007, 85, 1810-1818
130. Kristensen, S.E.; Thomsen, M.S.; Hansen, H.H.; Timmermann, D.B.; Hay-Schmidt, A.; Mikkelsen, J.D. The 7 nicotinic receptor agonist SSR180711 increases activity regulated cytoskeleton protein (Arc) gene expression in the prefrontal cortex of rat. Neurosci. Lett., 2007, 418, 154-158
131. Søderman, A.; Thomsen, M.S.; Hansen, H.H.; Nielsen, E.Ø.; Jensen, M.S.; West, M.J.; Mikkelsen, J.D. The nicotinic 7 acetylcholine receptor agonist SSR180711 is unable to activate limbic neurons in mice overexpressing human amyloid- 1-42. Brain Res., 2008, 1227, 240-247
132. Haydar, S.N.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T.A.; Dunlop, J.; LaRosa, S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R. SAR and biological evaluation of SEN12333/WAY-317538: novel 7 nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem., 2009, 17, 5247-5258
133. Roncarati, R.; Scali, C.; Comery, T.A.; Grauer, S.M.; Aschmi, A.; Bothmann, H.; Jow, B.; Kowai, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Duniop, J.; Terstappen, G.C. Procognitive and neuroprotective activity of a novel 7 nicotinic acetyl choline receptor agonist for treatment of neurodegenerative and cognitive disorders. J. Pharmacol. Exp. Ther., 2009, 329, 459-468
134. Boess, F.G.; Vry, J.D.; Erb, C.; Flessner, T.; Hendrix, M.; Luithle, J.; Methfessel, C.; Riedl, B.; Schnizler, K.; van der Staay, F.-J.; van Kampen, M.; Wiese, W.B.; Koenig, G. The novel 7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3- yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther., 2007, 321, 716-725
135. Briggs, C.A.; Schrimpf, M.R.; Anderson, D.J.; Gubbins, E.J.; Grønlien, J.H.; Håkerud, M.; Ween, H.; Thorin-Hagene, K.; Malysz, J.; Li, J.; Bunnelle, W.H.; Gopalakrishnan, M.; Meyer, M.D. 7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. Br. J. Pharmacol., 2008, 153, 1054-1061
136. Anderson, D.J.; Bunnelle, W.; Suber, B.; Du, J.; Surowy, C.; Tribollet, E.; Marguerat, A.; Bertrand, D.; Gopalakrishnan, M [3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5- aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity 7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J. Pharmacol. Exp. Ther., 2008, 324, 179-187
137. Bitner, R.S.; Bunnelle, W.H.; Anderson, D.J.; Briggs, C.A.; Buccafusco, J.; Curzon, P.; Decker, M.W.; Frost, J.M.; Gronlien, J.H.; Gubbins, E.; Li, J.; Malysz, J.; Markosyan, S.; Marsh, K.; Meyer, M.D.; Nikkel, A.L.; Radek, R.J.; Robb, H.M.; Timmermann, D.; Sullivan, J.P.; Gopalakrishnan, M. Broad- spectrum efficacy across cognitive domains by 7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci., 2007, 27, 10578-10587
138. Tietje, K.R.; Anderson, D.J.; Bitner, R.S.; Blomme, E.A.; Brackemeyer, P.J.; Briggs, C.A.; Browman, K.E.; Bury, D.; Curzon, P.; Drescher, K.U.; Frost, J.M.; Fryer, R.M.; Fox, G.B.; Gronlien, J.H.; Håkerud, M.; Gubbins, E.J.; Halm, S.; Harris, R.; Helfrich, R.J.; Kohlhaas, K.L.; Law, D.; Malysz, J.; Marsh, K.C.; Martin, R.L.; Meyer, M.D.; Molesky, A.L.; Nikkel, A.L.; Otte, S.; Pan, L.; Puttfarcken, P.S.; Radek, R.J.; Robb, H.M.; Spies, E.; Thorin-Hagene, K.; Waring, J.F.; Ween, H.; Xu, H.; Gopalakrishnan, M.; Bunnelle, W.H. Preclinical characterization of A-582941: a novel 7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther., 2008, 14, 65-82
139. Bitner, R.S.; Nikkel, A.L.; Markosyan, S.; Otte, S.; Puttfarcken, P.; Gopalakrishnan, M. Selective 7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3 and decreases tau phosphorylation in vivo. Brain Res., 2009, 1265, 65-74
140. Bunnelle, W.H.; Tietje, K.R.; Frost, J.M.; Peters, D.; Ji, J.; Li, T.; Scanio, M.J.C.; Shi, L.; Anderson, D.J.; Dyhring, T.; Grønlien, J.H.; Ween, H.; Thorin-Hagene, K.; Meyer, M.D. Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either 4 2 or 7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity. J. Med. Chem., 2009, 52, 4126-4141
141. Feuerbach, D.; Nozulak, J.; Lingenhoehl, K.; McAllister, K.; Hoyer, D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor 7 selective agonist. Neurosci. Lett., 2007, 416, 61-65
142. Feuerbach, D.; Lingenhoehl, K.; Olpe, H.-R.; Vassout, A.; Gentsch, C.; Chaperon, F.; Nozulak, J.; Enz, A.; Bilbe, G.; McAllister, K.; Hoyer, D. The selective nicotinic acetylcholine receptor 7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology, 2008, 56, 254-263
143. Enz, A.; Feuerbach, D.; Frederiksen, M.U.; Gentsch, C.; Hurth, K.; Müller, W.; Nozulak, J.; Roy, B.L. Gamma-lactams - A novel scaffold for highly potent and selective 7 nicotinic acetylcholine receptor agonists. Bioorg. Med. Chem. Lett., 2009, 19, 1287-1291
144. Baker, S.R.; Boot, J.; Brunavs, M.; Dobson, D.; Green, R.; Hayhurst, L.; Keenan, M.; Wallace, L. High affinity ligands for the 7 nicotinic receptor that show no cross-reactivity with 5-HT3 receptor. Bioorg. Med. Chem. Lett., 2005, 15, 4727-4730
145. Rezvani, A.H.; Kholdebarin, E.; Brucato, F.H.; Callahan, P.M.; Lowe, D.A.; Levin, E.D. Effect of R3487/MEM3454, a novel nicotinic 7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 269-275
146. Sabbagh, M.N. Drug development for Alzheimer's disease: where are we now and where are weheaded? Am. J. Geriatr. Pharmacother., 2009, 7, 167-185
147. Lopez-Hernandez, G.; Placzek, A.N.; Thinschmidt, J.S.; Lestage, P.; Trocme-Thibierge, C.; Morain, P.; Papke, R.L. Partial agonist and neuromodulatory activity of S 24795 for 7 nAChR responses of hippocampal interneurons. Neuropharmacology, 2007, 53, 134-144
148. Lagostena, L.; Trocme-Thibierge, C.; Morain, P.; Cherubini, E. The partial 7 nicotinic acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology, 2008, 54, 676-685
149. Beracochea, D.; Boucard, A.; Trocme-Thibierge, C.; Morain, P. Improvement of contextual memory by S 24795 in aged mice: comparison with memantine. Psychopharmacology (Berl), 2008, 196, 555-564
150. Marighetto, A.; Valerio, S.; Desmedt, A.; Philippin, J.N.; Trocmé- Thibierge, C.; Morain, P. Comparative effects of the 7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against age-related deficits in declarative and working memory in mice. Psychopharmacology (Berl), 2008, 197, 499-508
151. Maricq, A.V.; Peterson, A.S.; Brake, A.J.; Myers, R.M.; Julius, D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science, 1991, 254, 432-437
152. Macor, J.E.; Gurley, D.; Lanthorn, T.; Loch, J.; Mack, R.A.; Mullen, G.; Tran, O.; Wright, N.; Gordon, J.C. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective 7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett., 2001, 11, 319-321
153. Papke, R.L.; Porter Papke, J.K.; Rose, G.M. Activity of 7- selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes. Bioorg. Med. Chem. Lett., 2004, 14, 1849-1853
154. Hashimoto, K.; Iyo, M.; Freedman, R.; Stevens, K.E. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of 7 nicotinic acetylcholine receptors. Psychopharmacology (Berl), 2005, 183, 13-19
155. Hashimoto, K.; Fujita, Y.; Ishima, T.; Hagiwara, H.; Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of 7 nicotinic receptors. Eur. J. Pharmacol., 2006, 553, 191-195
156. Koike, K.; Hashimoto, K.; Takai, N.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Nakazato, M.; Okamura, N.; Stevens, K.E.; Freedman, R.; Iyo, M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res., 2005, 76, 67-72
157. Toyohara, J.; Wu, J.; Hashimoto, K. Recent development of radioligands for imaging 7 nicotinic acetylcholine receptors in the brain. Curr. Top. Med. Chem., 2010, (in press)
158. 11C]CHIBA- 1001 as a novel PET ligand for 7 nicotinic receptors in the brain: A PET study in conscious monkeys. PLoS One, 2008, 3, e3231
159. 11C]CHIBA-1001 for mapping 7 nicotinic receptors by positron emission tomography. Ann. Nucl. Med., 2009, 23, 301-309.